Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

3.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K
MicroRNAs01:22

MicroRNAs

23.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.9K
Experimental RNAi02:15

Experimental RNAi

7.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The quality and reliability of short videos about cervical spondylosis on TikTok and Redbook: a cross-sectional study.

BMC musculoskeletal disorders·2026
Same author

Impact of continuous serratus plane analgesia on quality of recovery after video-assisted thoracic surgery: a prospective double-blind, randomized, placebo-controlled trial.

Regional anesthesia and pain medicine·2026
Same author

High-flow nasal cannula for hypoxia in the post-anesthetic recovery unit: A systematic review and meta-analysis.

World journal of critical care medicine·2026
Same author

HIF-1α/HO-1 Axis Promotes Ferroptosis and Impairs Periodontal Tissue Repair in Periodontitis.

Journal of clinical periodontology·2026
Same author

The potential role of sex related differences of the microbiome and its impact on calcific aortic stenosis: a narrative review.

Biology of sex differences·2026
Same author

miRNA-26b Is Associated with Increased Connexin-40 Expression in Endothelial Cells Under Flow Conditions.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Jan 11, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.9K

MicroRNA-26b-/- augments atherosclerosis, while mimic-loaded nanoparticles reduce atherogenesis.

Linsey J F Peters1,2, Kiril Bidzhekov1, Andrea Bonnin-Marquez2,3

  • 1Institute for Cardiovascular Prevention (IPEK), LMU Munich, 80336 Munich, Germany.

Cardiovascular Research
|November 12, 2025
PubMed
Summary
This summary is machine-generated.

MicroRNA-26b (miR-26b) has an atheroprotective role, reducing atherosclerotic lesion formation by suppressing inflammation. miR-26b mimic-loaded nanoparticles show therapeutic potential for treating atherosclerosis.

Keywords:
AtherosclerosisLipid nanoparticlesMacrophagesMicroRNA-26b

More Related Videos

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

7.7K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

720

Related Experiment Videos

Last Updated: Jan 11, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.9K
Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

7.7K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

720

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • MicroRNA Therapeutics

Background:

  • MicroRNAs (miRs) are implicated in atherosclerosis pathogenesis.
  • miR-26b is upregulated in human atherosclerotic plaques.
  • The specific role and therapeutic potential of miR-26b in atherosclerosis require elucidation.

Purpose of the Study:

  • To investigate the cell-specific effects of miR-26b on atherosclerosis development.
  • To determine the therapeutic potential of miR-26b in preclinical models.

Main Methods:

  • Utilized Apoe-/-Mir26b-/- and myeloid-specific knockout mice on a Western-type diet.
  • Assessed atherosclerotic plaque size, phenotype, and macrophage function.
  • Employed lipid nanoparticles (LNPs) for miR-26b mimic delivery in vitro and in vivo.

Main Results:

  • Apoe-/-Mir26b-/- mice exhibited significantly increased atherosclerotic lesion size in the aortic arch.
  • Loss of miR-26b in myeloid cells promoted a pro-inflammatory macrophage phenotype and altered plaque composition.
  • miR-26b mimics delivered via LNPs rescued these pro-atherosclerotic effects and demonstrated therapeutic potential.

Conclusions:

  • miR-26b plays a crucial atheroprotective role by reducing lesion formation, inflammation, and promoting collagen breakdown.
  • miR-26b mimic-loaded LNPs represent a promising therapeutic strategy for atherosclerosis.